Point72 Hong Kong LTD Immunovant, Inc. Transaction History

Point72 Hong Kong LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$3.93 - $6.37 $15,979 - $25,900	4,066 New	4,066 $23,000
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $8,118 - $13,571	-2,402 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.06 - $8.77 $9,310 - $16,136	1,840 Added 327.4%	2,402 $13,000
Q4 2021 Feb 14, 2022	BUY	$7.33 - $9.32 $4,119 - $5,237	562 New	562 $5,000
Q1 2021 May 17, 2021	SELL	$13.08 - $49.6 $32,242 - $122,264	-2,465 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$36.36 - $52.71 $43,777 - $63,462	-1,204 Reduced 32.82%	2,465 $114,000
Q3 2020 Nov 16, 2020	BUY	$22.61 - $38.9 $82,956 - $142,724	3,669 New	3,669 $129,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.